22-Ene-25-oxa-vitamin D: A new vitamin D analogue with profound immunosuppressive capacities

European Journal of Clinical Investigation

Volumn 35, Issue 5, 2005, Pages 343-349

  Daniel, C ^a   Schlauch, T ^a   Zugel U ^b,c   Steinmeyer, A ^b   Radeke, H H ^a   Steinhilber, D ^a   Stein, Jürgen ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Research Center Europe   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

1,25 dihydroxyvitamin D3; Immunmodulation; PBMCs; Th1 Th2 immune response; Vitamin D analogues

Indexed keywords

25 OXAVITAMIN D 22 ENE; ANTIINFLAMMATORY AGENT; CALCITRIOL; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; PHYTOHEMAGGLUTININ; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; ZK 156979;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INHIBITION KINETICS; MACROPHAGE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; VITAMIN D METABOLISM;

CALCITRIOL; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-4; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; T-LYMPHOCYTES, HELPER-INDUCER; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN D;

EID: 18844439139     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01492.x     Document Type: Article

References (50)

1. Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J 2001;15:2579-85.
2. Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-le-Grand) 2003;49:277-300.
3. Lin R, White JH. The pleiotropic actions of vitamin D. Bioessays 2004;26:21-8.
4. van Etten E, Decallonne B, Mathieu C. 1,25-dihydroxycholecalciferol: endocrinology meets the immune system. Proc Nutr Soc 2002;61:375-80.
5. Griffin MD, Xing N, Kumar R. Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu Rev Nutr 2003;23:117-45.
6. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D (3) analogs as immunomodulatory agents. Trends Mol Med 2002;8:174-9.
7. Tocchini-Valentini G, Rochel N, Wurtz JM, Moras D. Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification. J Med Chem 2004;47:1956-61.
8. Malloy PJ, Pike JW, Feldman D. The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocr Rev 1999;20:156-88.
9. Sunn KL, Cock TA, Crofts LA, Eisman JA, Gardiner EM. Novel N-terminal variant of human VDR. Mol Endocrinol 2001;15:1599-609.
10. 3. J Steroid Biochem Mol Biol 1995;53:599-602.
11. 3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab 1983;57:1308-10.
12. 3 receptors in human leukocytes. Science 1983;221:1181-3.
13. 3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest 1984;74:657-61.
14. 3-binding macromolecules in human B lymphocytes: effects on immunoglobulin production. J Immunol 1986;136:2734-40.
15. 3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 2000;164:4443-51.
16. 3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 1998;101:252-62.
17. 3 attenuates the expression of experimental murine lupus of MRL/1 mice. Autoimmunity l992;12:143-8.
18. 3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991;87:1103-7.
19. 3. Diabetologia 1994;37:552-8.
20. Mattner F, Smiroldo S, Galbiati F, Muller M, Di Lucia P, Poliani PL et al. Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D (3). Eur J Immunol 2000;30:498-508.
21. 3 selectively reduces interleukin-2 levels and proliferation of human T cell lines in vitro. Immunol Lett 1993;35:177-82.
22. 3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 1996;93:7861-4.
23. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984;74:2136-43.
24. 3 in rheumatoid arthritis patients. Clin Exp Rheumatol 1999;17:453-6.
25. 3) for the treatment of psoriasis. Br J Dermatol 1996;134:1070-8.
26. 3 analog with reduced hypercalcemic activity. J Invest Dermatol 2002;119:1434-42.
27. Verstuyf A, Segaert S, Verlinden L, Bouillon R, Mathieu C. Recent developments in the use of vitamin D analogues. Expert Opin Invest Drugs 2000;9:443-55.
28. van Halteren AG, van Etten E, de Jong EC, Bouillon R, Roep BO, Mathieu C. Redirection of human autoreactive T-cells upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D (3). Diabetes 2002;51:2119-25.
29. 3 as pluripotent immunomodulators. J Cell Biochem 2003;88:223-6.
30. 3 in combination with a short induction course of cyclosporin A. Endocrinology 1998;139:95-102.
31. Steinmeyer A, Kirsch G, Neef G, Schwarz K. New synthetic vitamin D analogs with antiproliferative activities. Curr Pharm Des 2000;6:767-89.
32. Werz O, Wiesinger H, Steinmeyer A, Steinhilber D. New vitamin D receptor agonists with decreased metabolic stability. Biochem Pharmacol 2000;59:1597-601.
33. Carlberg C. Molecular basis of the selective activity of vitamin D analogues. J Cell Biochem 2003;88:274-81.
34. 3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol 1995;15:5789-99.
35. 3 as a natural regulator of human immune functions. J Invest Dermatol Symp Proc 1996;1:68-71.
36. 3 has a direct effect on naive CD4 (+) T cells to enhance the development of Th2 cells. J Immunol 2001;167:4974-80.
37. 3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactiveT cell activation. J Immunol 2000;164:2405-11.
38. Mosmann TR. Properties and functions of interleukin-10. Adv Immunol 1994;56:1-26.
39. 3 and cytokines on the expression of MHC antigens, complement receptors and other antigens on human blood monocytes and U937 cells: role in cell differentiation, activation and phagocytosis. Immunology 1997;90:286-93.
40. 3 shows strong and additive immunomodulatory effects with cyclosporine A in rat renal allotransplants. Kidney Int 2002;61:288-96.
41. + T cells. J Immunol 2002;168:1181-9.
42. 3 inhibits not only Th1 but also Th2 differentiation in human cord blood T cells. Pediatr Res 2002;52:12-8.
43. 3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001;167:1945-53.
44. Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L. A 1alpha,25-dihydroxyvitamm D (3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002;51:1367-74.
45. 3 enhances the generation of nonspecific suppressor cells while inhibiting the induction of cytotoxic cells in a human MLR. Cell Immunol 1992;140:400-9.
46. Chatenoud L, Salomon B, Bluestone JA. Suppressor T cells - they're back and critical for regulation of autoimmunity! Immunol Rev 2001;182:149-63.
47. Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF et al. In vitro generation of interleukin 10-producing regulatory CD4 (+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002;195:603-16.
48. 3: a transcriptional modulator of the interferon-gamma gene. Eur J Immunol 1998;28:3017-30.
49. Murphy KM, Ouyang W, Farrar JD, Yang J, Ranganath S, Asnagli H et al. Signaling and transcription in T helper development. Annu Rev Immunol 2000;18:451-94.
50. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 2003;21:713-58.